A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

I6A-MC-CBBE -

The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Lung Cancer
What the trial is testing?
Necitumumab, Samotolisib
Could I receive a Placebo?
No
Enrollment Goal
31
Trial Dates
Jul 1, 2015 - Sep 1, 2017
How long will I be in the trial?
Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.